Équipe
Etienne Chatelut

DIAD :

Individualisation des doses de médicaments anticancéreux

Les spécificités
de notre axe de recherche

Pharmacocinétique

Pharmacogénétique

Individualisation des traitements

Suivi thérapeutique pharmacologique

Chromatographie liquide

Molécules radiomarquées théranostiques

Prédisposition génétique familiale

DES PROJETS
DE RECHERCHE

LES FOCUS
DE L’ÉQUIPE

Découvrir

Focus recherche 2022 équipe DIAD

Lire plus

Workshop – Computational analysis and multiomics in oncology

Lire plus

Effet de la co-administration de deux solutions d’acides aminés sur l’élimination et les effets indésirables du 177Lu-Dotatate

Lire plus

Première saison des Apprentis Chercheurs au CRCT

Lire plus

Intérêt du dépistage de l’activité de la DPD chez tous les patients traités par fluoropyrimidines.

Lire plus

Comprendre

Septembre en Or, mois international des cancers de l’enfant

Lire plus

10 ans de recherche contre le Cancer : Toulouse au cœur de la lutte

Lire plus

La cellule tumorale

Lire plus

L’immunothérapie en cancérologie

Lire plus

Les thérapies ciblées en cancérologie

Lire plus

Participer

TOW2025 J-30 inscription anticipée

Lire plus

PRODUCTIONS SCIENTIFIQUES

PUBLICATIONS 2024
Malier, Marie, Marie-Hélène Laverriere, Maxime Henry, Malika Yakoubi, Pascale Bellaud, Cécile Arellano, Anthony Sébillot, et al. “Tumor-Associated Macrophages Confer Resistance to Chemotherapy (Trifluridine/Tipiracil) in Digestive Cancers by Overexpressing Thymidine Phosphorylase.” Cancer Letters 606 (October 23, 2024): 217307. https://doi.org/10.1016/j.canlet.2024.217307.
Mc Laughlin, Anna M., Thomas Helland, Fenja Klima, Stijn L. W. Koolen, Ron H. N. van Schaik, Ron H. J. Mathijssen, Patrick Neven, et al. “Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort.” Clinical Pharmacology and Therapeutics 116, no. 3 (September 2024): 690–702. https://doi.org/10.1002/cpt.3238.
Thomas, Fabienne, Manon Launay, Laure Raymond, Jérôme Guitton, Marie-Anne Loriot, Etienne Chatelut, Vincent Haufroid, and Marie-Christine Etienne-Grimaldi. “Reply to: ‘Is Uracil Enough for Effective Pre-Emptive DPD Testing?’” Clinical Chemistry and Laboratory Medicine, August 15, 2024. https://doi.org/10.1515/cclm-2024-0889.
Launay, Manon, Laure Raymond, Jérôme Guitton, Marie-Anne Loriot, Etienne Chatelut, Vincent Haufroid, Fabienne Thomas, and Marie-Christine Etienne-Grimaldi. “Can We Identify Patients Carrying Targeted Deleterious DPYD Variants with Plasma Uracil and Dihydrouracil? A GPCO-RNPGx Retrospective Analysis.” Clinical Chemistry and Laboratory Medicine, June 19, 2024. https://doi.org/10.1515/cclm-2024-0317.
Puangpetch, Apichaya, Fabienne Thomas, Usanarat Anurathapan, Samart Pakakasama, Suradej Hongeng, Jiratha Rachanakul, Santirhat Prommas, et al. “Model-Informed Precision Dosing of Intravenous Busulfan in Thai Pediatrics Undergoing Hematopoietic Stem Cell Transplantation.” Therapeutic Drug Monitoring, May 14, 2024. https://doi.org/10.1097/FTD.0000000000001225.
Blanchet, Benoit, Alexandre Xu-Vuilard, Anne Jouinot, Florent Puisset, David Combarel, Olivier Huillard, Félicien Le Louedec, et al. “Exposure-Response Relationship of Cabozantinib in Patients with Metastatic Renal Cell Carcinoma Treated in Routine Care.” British Journal of Cancer 130, no. 6 (April 2024): 961–69. https://doi.org/10.1038/s41416-024-02585-y.
Lambert, Marie, Mathieu Alonso, Caroline Munzer, Marie-Christine Zimoch, Laurence Malard, Marion Gambart, Marie-Pierre Castex, Carla Martins, Marlène Pasquet, and Etienne Chatelut. “Prospective Validation of an Equation Based on Plasma Cystatin C for Monitoring the Glomerular Filtration Rate in Children Treated with Cisplatin or Ifosfamide for Cancer.” Cancer Chemotherapy and Pharmacology 93, no. 4 (April 2024): 393–95. https://doi.org/10.1007/s00280-023-04597-6.
Le Teuff, Gwénaël, Nathalie Cozic, Jean-Christophe Boyer, Valérie Boige, Robert B. Diasio, Julien Taieb, Didier Meulendijks, et al. “Dihydropyrimidine Dehydrogenase Gene Variants for Predicting Grade 4-5 Fluoropyrimidine-Induced Toxicity: FUSAFE Individual Patient Data Meta-Analysis.” British Journal of Cancer 130, no. 5 (March 2024): 808–18. https://doi.org/10.1038/s41416-023-02517-2.
PUBLICATIONS 2023
Ranchon, Florence, Étienne Chatelut, Juliette Lambert, Pierre Sesques, Constance Thibault, Isabelle Madelaine, Catherine Rioufol, Véronique Diéras, and Jean-Louis Cazin. “[Antibody drug conjugates (ADC) and bispecific antibodies in oncology - report of the 2022 Saint Louis day].” Bulletin Du Cancer, October 10, 2023, S0007-4551(23)00345-4. https://doi.org/10.1016/j.bulcan.2023.07.009.
Al Saati, Ayman, Pierre Vande Perre, Julien Plenecassagnes, Julia Gilhodes, Nils Monselet, Bastien Cabarrou, Norbert Lignon, et al. “Multigene Panel Sequencing Identifies a Novel Germline Mutation Profile in Male Breast Cancer Patients.” International Journal of Molecular Sciences 24, no. 18 (September 20, 2023): 14348. https://doi.org/10.3390/ijms241814348.
Boumaza, Xavier, Margaux Lafaurie, Emmanuel Treiner, Ondine Walter, Gregory Pugnet, Guillaume Martin-Blondel, Damien Biotti, et al. “Infectious Risk When Prescribing Rituximab in Patients with Hypogammaglobulinemia Acquired in the Setting of Autoimmune Diseases.” International Immunopharmacology 120 (July 2023): 110342. https://doi.org/10.1016/j.intimp.2023.110342.
Valentin, Thibaud, Marie Lambert, Léonor Chaltiel, Ben Allal, Mourad Mseddi, Malika Yakoubi, Christine Chevreau, et al. “Population Pharmacokinetic Analysis Reveals No Impact of Aprepitant on the Pharmacokinetics of Ifosfamide, 2-Dechloroifosfamide, and 3-Dechloroifosfamide.” European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 185 (June 1, 2023): 106420. https://doi.org/10.1016/j.ejps.2023.106420.
Royer, B., M. Launay, J. Ciccolini, L. Derain, F. Parant, F. Thomas, and J. Guitton. “Impact of Renal Impairment on Dihydropyrimidine Dehydrogenase (DPD) Phenotyping.” ESMO Open 8, no. 3 (June 2023): 101577. https://doi.org/10.1016/j.esmoop.2023.101577.
Jong, Loek A. W. de, Marie Lambert, Nielka P. van Erp, Lukas de Vries, Etienne Chatelut, and Petronella B. Ottevanger. “Systemic Exposure to Cisplatin and Paclitaxel after Intraperitoneal Chemotherapy in Ovarian Cancer.” Cancer Chemotherapy and Pharmacology, March 9, 2023. https://doi.org/10.1007/s00280-023-04512-z.
Laloi, Louise, Natacha Chaumard Billotey, Pierre-Yves Dumas, Franciane Paul, Alban Villate, Célestine Simand, Luc Fornecker, et al. “Retrospective, Real-Life Study of Venetoclax plus Azacitidine or Low-Dose Cytarabine in French Patients with Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy.” Cancer Medicine 12, no. 6 (March 2023): 7175–81. https://doi.org/10.1002/cam4.5459.
Poumeaud, François, Florence Dalenc, Quentin Mathevet, Aurélie Brice, Audrey Eche-Gass, Eleonora De Maio D’Esposito, Clémence Brac-de-la-Perriere, and Fabienne Thomas. “Phenotype/Genotype Discrepancy of DPD Deficiency Screening in a Patient With Severe Capecitabine Toxicity: A Case Report.” JCO Precision Oncology 7 (March 2023): e2200508. https://doi.org/10.1200/PO.22.00508.
Puisset, Florent, Félicien Le Louedec, Florence Dalenc, Lorène Verguet, Eleonora De Maio, Jean Louis Lacaze, Marion Montastruc, et al. “Investigating the Clinical Impact of Dose-Banding for Weekly Paclitaxel in Patients with Breast Cancer: A Retrospective and Monocentric Study.” British Journal of Clinical Pharmacology, February 28, 2023. https://doi.org/10.1111/bcp.15702.
Overbeek, J. K., R. Ter Heine, H. M. W. Verheul, E. Chatelut, M. A. Rudek, H. Gurney, R. Plummer, et al. “Off-Label, but on Target: The Evidence Needed to Implement Alternative Dosing Regimens of Anticancer Drugs.” ESMO Open 8, no. 1 (February 2023): 100749. https://doi.org/10.1016/j.esmoop.2022.100749.
Maillard, Maud, Manon Launay, Bernard Royer, Jérôme Guitton, Elodie Gautier-Veyret, Sophie Broutin, Camille Tron, et al. “Quantitative Impact of Pre-Analytical Process on Plasma Uracil When Testing for Dihydropyrimidine Dehydrogenase Deficiency.” British Journal of Clinical Pharmacology 89, no. 2 (February 2023): 762–72. https://doi.org/10.1111/bcp.15536.
Puisset, Florent, Mourad Mseddi, Loïc Mourey, Damien Pouessel, Benoit Blanchet, Etienne Chatelut, and Christine Chevreau. “Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer.” Cancers 15, no. 1 (January 3, 2023): 313. https://doi.org/10.3390/cancers15010313.
Le Louedec, Félicien, Florent Puisset, Etienne Chatelut, and Michel Tod. “Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug-Drug Interaction and Improving Clinical Practice.” Clinical Pharmacokinetics 62, no. 1 (January 2023): 55–66. https://doi.org/10.1007/s40262-022-01200-8.
PUBLICATIONS 2022
Etienne-Grimaldi, Marie-Christine, Nicolas Pallet, Valérie Boige, Joseph Ciccolini, Laurent Chouchana, Chantal Barin-Le Guellec, Aziz Zaanan, et al. “Current Diagnostic and Clinical Issues of Screening for Dihydropyrimidine Dehydrogenase Deficiency.” European Journal of Cancer (Oxford, England: 1990) 181 (December 9, 2022): 3–17. https://doi.org/10.1016/j.ejca.2022.11.028.
Thomas, Fabienne, Manon Launay, Jérôme Guitton, Marie-Anne Loriot, Jean-Christophe Boyer, Vincent Haufroid, Marie-Christine Etienne-Grimaldi, Bernard Royer, and GPCO-UNICANCER Group. “Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!” Clinical Pharmacology and Therapeutics, November 22, 2022. https://doi.org/10.1002/cpt.2772.
Maillard, Maud, Cécile Arellano, Christelle Vachoux, Christine Chevreau, Nicolas J. Cabaton, Frédéric Pont, Nathalie Saint-Laurent, Thierry Lafont, Etienne Chatelut, and Fabienne Thomas. “Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury.” Metabolites 12, no. 9 (September 11, 2022): 852. https://doi.org/10.3390/metabo12090852.
Jong, Loek A. W. de, Fortuné M. K. Elekonawo, Marie Lambert, Jan Marie de Gooyer, Henk M. W. Verheul, David M. Burger, Johannes H. W. de Wilt, et al. “Correction to: Wide Variation in Tissue, Systemic, and Drain Fluid Exposure after Oxaliplatin‑based HIPEC: Results of the GUTOX Study.” Cancer Chemotherapy and Pharmacology, June 22, 2022. https://doi.org/10.1007/s00280-022-04450-2.
Maillard, Maud, Baptiste Louveau, Paul Vilquin, Lauriane Goldwirt, Fabienne Thomas, and Samia Mourah. “Pharmacogenomics in Solid Cancers and Hematologic Malignancies: Improving Personalized Drug Prescription.” Therapie 77, no. 2 (April 2022): 171–83. https://doi.org/10.1016/j.therap.2021.11.003.
Krache, Anis, Charlotte Fontan, Carine Pestourie, Manuel Bardiès, Yann Bouvet, Pierre Payoux, Etienne Chatelut, Melanie White-Koning, and Anne-Sophie Salabert. “Preclinical Pharmacokinetics and Dosimetry of an 89Zr Labelled Anti-PDL1 in an Orthotopic Lung Cancer Murine Model.” Frontiers in Medicine 8 (January 31, 2022): 741855. https://doi.org/10.3389/fmed.2021.741855.
Grand, Anaïs, Jean-Baptiste Desbouges, Coralie Guillemot, Coline Spinau, and Florent Puisset. “Still Some Constraints Before Generalization of Remote Clinical Trial Monitoring: A Pharmacist’s Point of View of the Lessons From the COVID-19 Pandemic.” JCO Oncology Practice, January 6, 2022, OP2100749. https://doi.org/10.1200/OP.21.00749.
Lambert, Marie, Lawrence Dierickx, Séverine Brillouet, Frédéric Courbon, and Etienne Chatelut. “Comparison of Two Types of Amino Acid Solutions on 177Lu-Dotatate Pharmacokinetics and Pharmacodynamics in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors.” Current Radiopharmaceuticals 15, no. 2 (2022): 164–72. https://doi.org/10.2174/1874471015666211228123525.
PUBLICATIONS 2021
Malier, Marie, Khaldoun Gharzeddine, Marie-Hélène Laverriere, Sabrina Marsili, Fabienne Thomas, Thomas Decaens, Gael Roth, and Arnaud Millet. “Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer.” Cancer Research 81, no. 23 (December 1, 2021): 5963–76. https://doi.org/10.1158/0008-5472.CAN-21-1572.
Clarke, William A., Etienne Chatelut, Alan K. Fotoohi, Richard A. Larson, Jennifer H. Martin, Ron H. J. Mathijssen, and Salvatore J. Salamone. “Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Consensus Guidelines for Imatinib Therapy.” European Journal of Cancer (Oxford, England: 1990) 157 (November 2021): 428–40. https://doi.org/10.1016/j.ejca.2021.08.033.
Le Louedec, Félicien, Florent Puisset, Fabienne Thomas, Étienne Chatelut, and Mélanie White-Koning. “Easy and Reliable Maximum a Posteriori Bayesian Estimation of Pharmacokinetic Parameters with the Open-Source R Package Mapbayr.” CPT: Pharmacometrics & Systems Pharmacology 10, no. 10 (October 2021): 1208–20. https://doi.org/10.1002/psp4.12689.
Gallais, Fanny, Loïc Ysebaert, Fabien Despas, Sandra De Barros, Lucie Obéric, Ben Allal, Etienne Chatelut, and Mélanie White-Koning. “Population PK-PD Modeling of Circulating Lymphocyte Dynamics in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment.” Clinical Pharmacology and Therapeutics 110, no. 1 (July 2021): 220–28. https://doi.org/10.1002/cpt.2189.
White-Koning, Melanie, Marie Noëlle Paludetto, Félicien Le Louedec, Laurence Gladieff, Christine Chevreau, Etienne Chatelut, and Florent Puisset. “Correction to: Formulae Recently Proposed to Estimate Renal Glomerular Filtration Rate Improve the Prediction of Carboplatin Clearance.” Cancer Chemotherapy and Pharmacology 88, no. 1 (July 2021): 171. https://doi.org/10.1007/s00280-021-04268-4.
Thomas, F., M. Maillard, M. Launay, C. Tron, M.-C. Etienne-Grimaldi, E. Gautier-Veyret, V. Haufroid, et al. “Artificial Increase of Uracilemia during Fluoropyrimidine Treatment Can Lead to DPD Deficiency Misinterpretation.” Annals of Oncology: Official Journal of the European Society for Medical Oncology 32, no. 6 (June 2021): 810–11. https://doi.org/10.1016/j.annonc.2021.02.020.
Mourey, Loïc, Félicien Le Louedec, Alain Ravaud, Marie-Noëlle Paludetto, Laurence Digue, Carlos Alberto Gomez-Roca, Thibaud Valentin, et al. “VOTRAGE Study: Phase I Dose-Escalation Study of Pazopanib in Unfit Older Patients.” Journal of Geriatric Oncology 12, no. 5 (June 2021): 759–64. https://doi.org/10.1016/j.jgo.2021.02.006.
Puszkiel, Alicja, Cécile Arellano, Christelle Vachoux, Alexandre Evrard, Valérie Le Morvan, Jean-Christophe Boyer, Jacques Robert, et al. “Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer.” Clinical Pharmacology and Therapeutics 109, no. 5 (May 2021): 1244–55. https://doi.org/10.1002/cpt.2077.
Maillard, Maud, Audrey Eche-Gass, Mony Ung, Aurélie Brice, Sabrina Marsili, Marion Montastruc, Florent Puisset, and Fabienne Thomas. “Severe Toxicity of Capecitabine in a Patient with DPD Deficiency after a Safe FEC-100 Experience: Why We Should Test DPD Deficiency in All Patients before High-Dose Fluoropyrimidines.” Cancer Chemotherapy and Pharmacology 87, no. 4 (April 2021): 579–83. https://doi.org/10.1007/s00280-021-04233-1.
Chevreau, Christine, Christophe Massard, Aude Flechon, Rémy Delva, Gwenaëlle Gravis, Jean-Pierre Lotz, Jacques-Olivier Bay, et al. “Multicentric Phase II Trial of TI-CE High-Dose Chemotherapy with Therapeutic Drug Monitoring of Carboplatin in Patients with Relapsed Advanced Germ Cell Tumors.” Cancer Medicine 10, no. 7 (April 2021): 2250–58. https://doi.org/10.1002/cam4.3687.
Medrano, Chloé, Lucie Oberic, Florent Puisset, Christian Recher, Delphine Larrieu-Ciron, Loïc Ysebaert, Caroline Protin, et al. “Life-Threatening Complications after High-Dose Methotrexate and the Benefits of Glucarpidase as Salvage Therapy: A Cohort Study of 468 Patients.” Leukemia & Lymphoma 62, no. 4 (April 2021): 846–53. https://doi.org/10.1080/10428194.2020.1846733.
Chatelut, Etienne, Jeroen J. M. A. Hendrikx, Jennifer Martin, Joseph Ciccolini, and Dirk Jan A. R. Moes. “Unraveling the Complexity of Therapeutic Drug Monitoring for Monoclonal Antibody Therapies to Individualize Dose in Oncology.” Pharmacology Research & Perspectives 9, no. 2 (April 2021): e00757. https://doi.org/10.1002/prp2.757.
Le Louedec, Félicien, Fanny Gallais, Fabienne Thomas, Mélanie White-Koning, Ben Allal, Caroline Protin, Loïc Ysebaert, Étienne Chatelut, and Florent Puisset. “Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite Data.” Pharmaceuticals (Basel, Switzerland) 14, no. 2 (February 18, 2021). https://doi.org/10.3390/ph14020162.
Larroque-Lombard, Anne-Laure, Etienne Chatelut, Jean-Pierre Delord, Diane-Charlotte Imbs, Philippe Rochaix, Bertrand Jean-Claude, and Ben Allal. “Design and Mechanism of Action of a New Prototype of Combi-Molecule ‘Programed’ to Release Bioactive Species at a PH Range Akin to That of the Tumor Microenvironment.” Pharmaceuticals (Basel, Switzerland) 14, no. 2 (February 16, 2021). https://doi.org/10.3390/ph14020160.
PUBLICATIONS 2020
Maillard, Maud, Christine Chevreau, Félicien Le Louedec, Manon Cassou, Caroline Delmas, Laure Gourdain, Jean-Yves Blay, et al. “Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma.” Cancers 12, no. 12 (December 4, 2020): 3647. https://doi.org/10.3390/cancers12123647.
Le Louedec, Félicien, Fanny Leenhardt, Clémence Marin, Étienne Chatelut, Alexandre Evrard, and Joseph Ciccolini. “Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective.” Vaccines 8, no. 4 (October 31, 2020): 632. https://doi.org/10.3390/vaccines8040632.
Lambert, Marie, Melanie White‐Koning, Mathieu Alonso, Arnaud Garnier, Gwennaelle Alphonsa, Chloé Puiseux, Caroline Munzer, et al. “Plasma Cystatin C Is a Marker of Renal Glomerular Injury in Children Treated with Cisplatin or Ifosfamide.” Pediatric Blood & Cancer, October 15, 2020. https://doi.org/10.1002/pbc.28747.
Le Louedec, Félicien, and Etienne Chatelut. “Correlation between Bevacizumab Exposure and Survival Does Not Necessarily Imply Causality. Letter to the Editor.” The Oncologist, October 12, 2020, onco.13564. https://doi.org/10.1002/onco.13564.
Maillard, Maud, Félicien Le Louedec, Fabienne Thomas, and Etienne Chatelut. “Diversity of Dose-Individualization and Therapeutic Drug Monitoring Practices of Platinum Compounds: A Review.” Expert Opinion on Drug Metabolism & Toxicology, October 5, 2020, 1–19. https://doi.org/10.1080/17425255.2020.1789590.
Gallais, Fanny, Lucie Oberic, Stanislas Faguer, Suzanne Tavitian, Thierry Lafont, Sabrina Marsili, Aurélie Brice, Etienne Chatelut, and Florent Puisset. “Body Surface Area Dosing of High-Dose Methotrexate Should Be Reconsidered, Particularly in Overweight, Adult Patients.” Therapeutic Drug Monitoring Publish Ahead of Print (September 10, 2020). https://doi.org/10.1097/FTD.0000000000000813.
Gallais, Fanny, Loïc Ysebaert, Fabien Despas, Sandra De Barros, Loïc Dupré, Anne Quillet-Mary, Caroline Protin, et al. “Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies.” Clinical Pharmacokinetics 59, no. 9 (September 2020): 1171–83. https://doi.org/10.1007/s40262-020-00884-0.
White-Koning, Melanie, Marie Noëlle Paludetto, Félicien Le Louedec, Laurence Gladieff, Christine Chevreau, Etienne Chatelut, and Florent Puisset. “Formulae Recently Proposed to Estimate Renal Glomerular Filtration Rate Improve the Prediction of Carboplatin Clearance.” Cancer Chemotherapy and Pharmacology, January 9, 2020. https://doi.org/10.1007/s00280-019-04020-z.
Metsu, David, Thomas Lanot, François Fraissinet, Didier Concordet, Véronique Gayrard, Manon Averseng, Alice Ressault, et al. “Comparing Ultrafiltration and Equilibrium Dialysis to Measure Unbound Plasma Dolutegravir Concentrations Based on a Design of Experiment Approach.” Scientific Reports 10, no. 1 (2020): 12265. https://doi.org/10.1038/s41598-020-69102-y.
Jong, Loek A. W. de, Fortuné M. K. Elekonawo, Marie Lambert, Jan Marie de Gooyer, Henk M. W. Verheul, David M. Burger, Johannes H. W. de Wilt, et al. “Wide Variation in Tissue, Systemic, and Drain Fluid Exposure after Oxaliplatin-Based HIPEC: Results of the GUTOX Study.” Cancer Chemotherapy and Pharmacology 86, no. 1 (2020): 141–50. https://doi.org/10.1007/s00280-020-04107-y.
Moeung, Sotheara, Christine Chevreau, Sabrina Marsili, Christophe Massart, Aude Fléchon, Rémy Delva, Gwenaëlle Gravis, et al. “Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors.” Pharmaceutical Research 37, no. 7 (2020): 147. https://doi.org/10.1007/s11095-020-02861-5.
Chatelut, Etienne, Félicien Le Louedec, and Gérard Milano. “Setting the Dose of Checkpoint Inhibitors: The Role of Clinical Pharmacology.” Clinical Pharmacokinetics 59, no. 3 (2020): 287–96. https://doi.org/10.1007/s40262-019-00837-2.
PUBLICATIONS 2019
Paludetto, Marie-Noëlle, Jean-Luc Stigliani, Anne Robert, Vania Bernardes-Génisson, Etienne Chatelut, Florent Puisset, and Cécile Arellano. “Involvement of Pazopanib and Sunitinib Aldehyde Reactive Metabolites in Toxicity and Drug-Drug Interactions in Vitro and in Patient Samples.” Chemical Research in Toxicology, September 26, 2019. https://doi.org/10.1021/acs.chemrestox.9b00205.
Soulès, Régis, Fabien Audouard-Combe, Emilie Huc-Claustre, Philippe de Medina, Arnaud Rives, Etienne Chatelut, Florence Dalenc, et al. “A Fast UPLC-HILIC Method for an Accurate Quantification of Dendrogenin A in Human Tissues.” The Journal of Steroid Biochemistry and Molecular Biology 194 (August 12, 2019): 105447. https://doi.org/10.1016/j.jsbmb.2019.105447.
Paludetto, Marie-Noëlle, Florent Puisset, Etienne Chatelut, and Cécile Arellano. “Identifying the Reactive Metabolites of Tyrosine Kinase Inhibitors in a Comprehensive Approach: Implications for Drug-Drug Interactions and Hepatotoxicity.” Medicinal Research Reviews, May 20, 2019. https://doi.org/10.1002/med.21577.
Puszkiel, Alicja, Gaëlle Noé, Audrey Bellesoeur, Nora Kramkimel, Marie-Noëlle Paludetto, Audrey Thomas-Schoemann, Michel Vidal, François Goldwasser, Etienne Chatelut, and Benoit Blanchet. “Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib.” Clinical Pharmacokinetics 58, no. 4 (April 2019): 451–67. https://doi.org/10.1007/s40262-018-0703-0.
Spinau, Coline, Florent Puisset, and Etienne Chatelut. “Carboplatine versus cisplatine - Pharmacocinétique, cytotoxicité, indications thérapeutiques.” ONKO+ 11, no. 85 (March 2019): 43–52.
Le Louedec, Félicien, Catherine Alix-Panabières, Thierry Lafont, Ben C. Allal, Renaud Garrel, Laurence Digue, Joël Guigay, et al. “Cetuximab Pharmacokinetic/Pharmacodynamics Relationships in Advanced Head and Neck Carcinoma Patients.” British Journal of Clinical Pharmacology, February 27, 2019. https://doi.org/10.1111/bcp.13907.
Puszkiel, Alicja, Cécile Arellano, Christelle Vachoux, Alexandre Evrard, Valérie Le Morvan, Jean-Christophe Boyer, Jacques Robert, et al. “Factors Affecting Tamoxifen Metabolism in Breast Cancer Patients; Preliminary Results of the French PHACS Study (NCT01127295).” Clinical Pharmacology and Therapeutics, February 20, 2019. https://doi.org/10.1002/cpt.1404.
Puszkiel, Alicja, Mathilde Bauriaud-Mallet, Roxane Bourgeois, Lawrence Dierickx, Frédéric Courbon, and Etienne Chatelut. “Evaluation of the Interaction of Amino Acid Infusion on 177Lu-Dotatate Pharmacokinetics in Patients with Gastroenteropancreatic Neuroendocrine Tumors.” Clinical Pharmacokinetics 58, no. 2 (February 2019): 213–22. https://doi.org/10.1007/s40262-018-0674-1.
Veal, Gareth J., Edward B. Amankwatia, Marie-Noëlle Paludetto, Till Möcklinghoff, Fiona Thomson, Nicolas André, Joseph Ciccolini, and Etienne Chatelut. “Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future Opportunities.” Therapeutic Drug Monitoring 41, no. 2 (2019): 142–59. https://doi.org/10.1097/FTD.0000000000000606.
Moeung, Sotheara, Christine Chevreau, Vianney Poinsignon, Jérôme Guitton, Bénédicte Lelièvre, Joseph Ciccolini, Laurence Gladieff, et al. “Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring.” Therapeutic Drug Monitoring 41, no. 1 (2019): 66–74. https://doi.org/10.1097/FTD.0000000000000569.

LES MEMBRES DE L’ÉQUIPE

Jeanne Petit
Doctorant / PhD student
Matthieu Gracia
Hospitalo-Universitaire / University teacher hospital practitioner
Lawrence Dierickx
Clinicien Chercheur / Researcher hospital practitioner
Christelle Vachoux
Technicien de laboratoire / Laboratory Technician
Fabienne Thomas
Enseignant chercheur / University researcher
Cécile Arellano
Enseignant chercheur / University researcher
Étienne Chatelut
Hospitalo-Universitaire / University teacher hospital practitioner
Marie Lambert
Clinicien Chercheur / Researcher hospital practitioner
Ben Allal
Clinicien Chercheur / Researcher hospital practitioner
Aurélie Brice
Technicien de laboratoire / Laboratory Technician
Sabrina Marsili
Technicien de laboratoire / Laboratory Technician
Félicien Le-Louedec
Doctorant / PhD student
Thierry Lafont
Technicien de laboratoire / Laboratory Technician
Malika Yakoubi
Ingénieur de laboratoire / laboratory engineer
Melanie White-Koning
Enseignant chercheur / University researcher
Ayman AL SAATI
Hospitalo-Universitaire / University teacher hospital practitioner

LES PARTENAIRES & FINANCIERS

Centre de Recherches en Cancérologie de Toulouse

Centre de Recherches contre le Cancer de Toulouse (Oncopole)

Toulouse - FR

Nous contacter

+33 5 82 74 15 75

Contact us

Nous rejoindre ?

Join-us

Pin It on Pinterest